Literature DB >> 11703617

Role of contact system activation in hemodialyzer-induced thrombogenicity.

R D Frank1, J Weber, H Dresbach, H Thelen, C Weiss, J Floege.   

Abstract

BACKGROUND: The contact system is generally believed to be the main trigger of the coagulation cascade during extracorporeal circulation. However, the extent of contact activation, its role for intradialytic thrombin generation as well as the influence of different dialyzer membranes have not been well established.
METHODS: In a novel full-scale ex vivo recirculation dialysis model, we investigated the thrombogenicity of three widely used hemodialyzers (Cuprophan Renak RA15-U, Polysulfone F6HPS and AN69XT Nephral 200). The activation of the contact system was evaluated using a newly developed ELISA for factor XIIa-C1-inhibitor complexes. Additionally, we determined free FXIIa (ELISA), thrombin-antithrombin (TAT) complexes, platelet factor 4 (PF4), complement activation (C5a), granulocyte elastase and blood cell counts. The findings in blood from normal volunteers were compared with factor XII-deficient blood.
RESULTS: With normal blood AN69 exhibited the highest thrombogenicity in comparison to Cuprophan and Polysulfone, as assessed by TAT generation and platelet consumption. AN69 caused a rapid increase of the FXIIa-C1-inhibitor complexes and of free FXIIa. Despite significant TAT generation with Cuprophan and Polysulfone free FXIIa remained unchanged and the FXIIa-C1-inhibitor complexes stayed below the detection limit. With factor XII-deficient blood Polysulfone exhibited the same TAT generation, whereas the thrombogenicity of AN69 was greatly reduced.
CONCLUSIONS: Our data challenge the common assumption that activation of the contact system with generation of FXIIa is the main trigger for coagulation and thrombus formation in hemodialysis. Only the negatively charged AN69 membrane with enhanced thrombogenicity strongly induced contact activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11703617     DOI: 10.1046/j.1523-1755.2001.00009.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  18 in total

1.  Cooling and reduced risk of clotting within the extracorporeal continuous renal replacement circuit.

Authors:  Sean M Bagshaw; Andrew Davenport
Journal:  Intensive Care Med       Date:  2008-10-08       Impact factor: 17.440

2.  Proteomic investigations on the effect of different membrane materials on blood protein adsorption during haemodialysis.

Authors:  Andrea Urbani; Vittorio Sirolli; Santina Lupisella; Stefano Levi-Mortera; Barbara Pavone; Luisa Pieroni; Luigi Amoroso; Roberto Di Vito; Sonia Bucci; Sergio Bernardini; Paolo Sacchetta; Mario Bonomini
Journal:  Blood Transfus       Date:  2012-05       Impact factor: 3.443

3.  Assessment of physical performance and body composition in male renal transplant patients.

Authors:  Andrea Petronio Rossi; Gianluigi Zaza; Marina Zanardo; Francesco Pedelini; Laura Dalla Verde; Chiara Caletti; Alessia D'Introno; Antonio Lupo; Mauro Zamboni
Journal:  J Nephrol       Date:  2018-03-17       Impact factor: 3.902

Review 4.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

5.  Factor XII activation markers do not reflect FXII dependence of thrombin generation induced by polyvinylchloride.

Authors:  Rolf Dario Frank; Ute Mueller; Regina Lanzmich; Jürgen Floege
Journal:  J Mater Sci Mater Med       Date:  2013-07-18       Impact factor: 3.896

6.  The clinical diagnosis of heparin-induced thrombocytopenia in patients receiving continuous renal replacement therapy.

Authors:  Chris E Holmes; Joe C Huang; Carina Cartelli; Alan Howard; Jeffrey Rimmer; Mary Cushman
Journal:  J Thromb Thrombolysis       Date:  2008-05-17       Impact factor: 2.300

7.  Angiotensin converting enzyme-regulated, noncholinergic sympathoadrenal catecholamine release mediates the cardiovascular actions of human 'new pressor protein' related to coagulation beta-factor XIIa.

Authors:  Peter C Papageorgiou; Demetrios Simos; Frans Boomsma; Rasmus Rojkjaer; Daniel H Osmond
Journal:  Can J Cardiol       Date:  2009-04       Impact factor: 5.223

Review 8.  Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces.

Authors:  Benjamin Tillman; David Gailani
Journal:  Semin Thromb Hemost       Date:  2017-09-12       Impact factor: 4.180

9.  Possible role of new pressor protein in hypertensive anephric hemodialysis patients.

Authors:  Rachel J Pearl; Peter C Papageorgiou; Michael Goldman; Akis A Amfilochiadis; Frans Boomsma; Rasmus Rojkjaer; Denis Geary; Daniel H Osmond
Journal:  Pediatr Nephrol       Date:  2003-08-12       Impact factor: 3.714

10.  In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process.

Authors:  M Golder; J Mewburn; D Lillicrap
Journal:  Thromb Haemost       Date:  2012-11-22       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.